**Question:** Surfactant production is accelerated by

A. Hypoxia
B. Hyperoxia
C. Inflammation
D. Inhibition of phospholipase A2

**Core Concept:** Surfactant is a complex mixture of lipids and proteins that reduces surface tension at the air-liquid interface in the lungs, enabling stable alveoli formation and preventing atelectasis. Its primary purpose is to facilitate gas exchange in the lungs.

**Why the Correct Answer is Right:** Surfactant production is accelerated by inhibiting phospholipase A2 (Option D). Phospholipase A2 is an enzyme that breaks down lung surfactant phospholipids, leading to decreased surfactant function and increased surface tension. Inhibition of phospholipase A2 helps maintain proper surfactant levels and prevents alveolar collapse.

**Why Each Wrong Option is Incorrect:**

A. Hypoxia (Option A) does not directly affect surfactant production. Hypoxia may lead to increased surfactant release through hypoxia-inducible factor (HIF) activation, but the main production occurs through cellular mechanisms.

B. Hyperoxia (Option B) can cause surfactant dysfunction due to lipid peroxidation and oxidative stress. However, it does not directly accelerate surfactant production.

C. Inflammation (Option C) can lead to surfactant dysfunction but does not specifically stimulate production. Inflammation-induced surfactant changes may worsen lung function.

**Clinical Pearl:** Understanding surfactant production and its regulation is crucial for managing neonatal respiratory distress syndrome (RDS), a common respiratory issue in premature infants. Proper surfactant levels and function are essential for optimal lung development, maturation, and gas exchange.

**Correct Answer:** D. Inhibition of phospholipase A2